AIM-PA.TO
Aimia Inc.$22.00
Jun 02, 2026
Market cap
$1.76M
52w range
—
P / E
—
EPS
—
Volume
—
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Aimia Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Communication Services+0.40%
- Financial Services+0.18%
- Energy+0.01%
- Technology-0.07%
- Consumer Cyclical-0.13%
- Consumer Defensive-0.45%
- Healthcare-0.50%
- Industrials-0.73%
- Basic Materials-1.36%
- Utilities-1.53%
- Real Estate-1.58%
Top industries (issuer's industry highlighted)
- Biotechnology+0.81%
- Electronic Gaming & Multimedia+3.97%
- Investment - Banking & Investment Services-2.87%
- Financial - Mortgages+2.35%
- Furnishings, Fixtures & Appliances+2.05%
- Coal-1.99%
- Chemicals-1.98%
- Solar-1.95%
- Medical - Healthcare Information Services+1.92%
- Travel Services+1.69%
- Gambling, Resorts & Casinos+1.65%
- Apparel - Footwear & Accessories+1.57%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancerglobenewswire.com·Jun 08, 2026
- AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancerglobenewswire.com·Jun 08, 2026
- Coiled Therapeutics strengthens its scientific benchproactiveinvestors.co.uk·Jun 08, 2026
- AIM ImmunoTech Inc. (AIM) Discusses Ampligen's Potential Role in Addressing BundiBugyo Ebola Outbreak Transcriptseekingalpha.com·Jun 04, 2026
- AIM ImmunoTech Releases Virtual Investor ‘What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease Preparednessglobenewswire.com·Jun 04, 2026
- AIM ImmunoTech Releases Virtual Investor ‘What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease Preparednessglobenewswire.com·Jun 04, 2026
- The Hour-Long Project We Never Would've Startedetftrends.com·Jun 03, 2026
- Candor Technology Integrates with Freddie Mac's AIM Check API to Automate Income Calculationsglobenewswire.com·May 13, 2026
Peers
No peer list available for AIM-PA.TO.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|